ClinicalTrials.gg
CompletedNCT01408888Updated Oct 7, 2014Results posted

A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

A Phase 1 interventional study of LY2189265 and Sitagliptin in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-10-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
48th of 54
29 · median 159
Started
2011
with 7 others
Phase 1
15 of 54
none open now
Registered
16th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 48th largest by enrollment, is one of 8 that started in 2011, is one of 15 in phase 1, and was the 16th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to study the effect of LY2189265 on how the body absorbs and processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects LY2189265 when they are taken together.

The duration of participation in this study is expected to be approximately 61 days. The study requires 2 clinic confinements (one of 2 nights and one of 19 nights duration).

The study involves 3 injections, subcutaneous, of 1.5 milligrams (mg) LY2189265 and 18 daily doses of 100 mg sitagliptin tablets administered orally.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • are males or females, diagnosed with T2DM (Type 2 Diabetes Mellitus) for ≥3 months prior to screening
  • male participants with female partners of , or partners who are pregnant or breastfeeding, agree to use a reliable method of from the time of the first dose until 3 months after the last dose of product, as determined by the investigator. The method may be one of the following:

    • condom with spermicidal agent
    • male participant sterilization
    • true abstinence (which is in line with the participant's usual lifestyle choice; withdrawal or calendar methods are not considered acceptable)
  • female participants not of child-bearing potential (that is, are or permanently sterilized [such as, tubal occlusion, hysterectomy, bilateral salpingectomy]). Such participants will not be required to use contraception but must test negative for pregnancy at the time of enrollment. Postmenopausal is defined as at least 1 year post cessation of menses (without an alternative medical cause) or at least 1 year of spontaneous amenorrhea, with follicle stimulating hormone (FSH) ≥40 milli-international units/milliliter (mIU/mL)
  • female participants who have undergone sterilization by tubal ligation: agree to use a condom in conjunction with spermicidal gel, foam, cream, film or suppository from the time of screening until 3 months after the last dose of investigational product. Such participants must also test negative for pregnancy at the time of enrollment
  • have a (BMI) of between 23.0 and 40.0 kilograms/meter squared (kg/m\^2), inclusive, at the time of screening
  • have T2DM controlled with diet and exercise alone, or are on a stable dose of metformin Immediate Release (IR) for at least 4 weeks prior to screening, or are on metformin Extended Release (ER) and are capable/willing to be switched onto metformin IR or washed out prior to the first dose of investigational product, or are on sulfonylureas, acarbose (or other disaccharidase inhibitors), thiazolidinediones, or meglitinides and are capable/willing to be washed out prior to the first dose of investigational product
  • have a fasting blood glucose value at screening ≤15.3 millimoles/liter (mmol/L) (275 milligrams/deciliter [mg/dL])
  • have a glycosylated (HbA1c) value at screening (or within 4 weeks prior to screening) of 6.5% to 10%
  • have clinical laboratory test results within normal reference range for the population or within normal reference range for the investigator site, or results with acceptable deviations that are judged to be not by the investigator. Abnormalities of serum glucose, serum lipids, urinary glucose, and urinary protein consistent with T2DM are acceptable.
  • have (CrCl) of greater than 50 milliliters/minute (mL/min) at screening estimated by the Cockcroft-Gault formula
  • have venous access sufficient to allow for blood sampling as per the protocol
  • are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Exclusion criteria

Exclusion Criteria:

  • are currently enrolled in, have completed or discontinued within the last 30 days from, a clinical trial involving an product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • have known allergies to glucagon-like-peptide 1 (GLP-1)-related compounds, including LY2189265 or to sitagliptin-related compounds or any components of either formulation
  • are persons who have previously completed or withdrawn from this study or any other study investigating LY2189265 in the 3 months prior to screening or have received glucagon-like peptides or incretin mimetics in the 3 months prior to screening
  • have taken insulin, chlorpropamide, or alpha-glucosidase inhibitors within 30 days prior to screening
  • have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • have poorly controlled hypertension (systolic blood pressure [BP] >160 millimeters of mercury [mmHg] and/or diastolic BP >100 mmHg) and/or evidence of labile BP including symptomatic postural hypotension
  • have a history or presence of respiratory, hepatic, renal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • have a history or presence of cardiovascular disorder (including myocardial infarction, cerebrovascular accident, venous thromboembolism, arrhythmia [judged by the investigator to be ], or angina) within the last year, have symptoms or signs of congestive heart failure, or are expected to require coronary artery bypass surgery or angioplasty
  • have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder, for example relevant esophageal reflux or gall bladder disease, or any gastrointestinal disease which impacts gastric emptying (GE) (such as, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by GLP-1 analogs or dipeptidyl peptidase-4 (DPP-4) inhibitors. Participants with dyslipidemia, and participants who had cholecystolithiasis (removal of gall stones) and/or cholecystectomy (removal of gall bladder) in the past, with no further sequelae, may be included in the study at the discretion of the screening physician
  • have any existing medical condition that might interfere with interpretation of the data, including a history of gastrointestinal surgery (with the exception of appendectomy performed more than 12 months ago), peptic ulceration, gastrointestinal bleeding, diabetic gastroparesis, ulcerative colitis, Crohn's disease, Irritable Bowel Syndrome (IBS), gastric bypass, or laparoscopic gastric banding
  • show evidence of significant active neuropsychiatric disease
  • have had 2 or more episodes of severe hypoglycemia within the last 6 months prior to screening
  • have personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC
  • regularly uses known drugs of abuse and/or show positive findings on urinary drug screening
  • intend to start new concomitant medication during the study, including over-the-counter and herbal medication, regularly use drugs that directly reduce gastrointestinal motility and/or regularly use systemic by oral, intravenous, or intramuscular route, or potent, inhaled, or intranasal steroids known to have a high rate of systemic absorption
  • show evidence of (HIV) infection and/or positive human HIV antibodies
  • show evidence of and/or positive hepatitis C antibody
  • show evidence of and/or positive hepatitis B surface antigen
  • have donated blood of more than 500 milliliters (mL) within the last month prior to screening
  • have an average weekly alcohol intake that exceeds 21 units per week (males up to age 65) and 14 units per week (males over 65 and females), or are unwilling to stop alcohol consumption from Day -3 of each period until after the last pharmacokinetic (PK) sample has been taken for that period, or to limit alcohol intake to a maximum of 2 units/day on all other days from screening through to follow-up. (1 unit = 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
  • smoke more than 10 cigarettes (or equivalent in nicotine) per day, and are unwilling to refrain from smoking on the day of LY2189265/sitagliptin administration or are unable to abide by Clinical Research Unit (CRU) restrictions on other inpatient days
  • are participants who, in the opinion of the investigator, are in any way unsuitable to participate in the study
  • have any medical conditions, medical history or are taking any medication which are
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    LY2189265, Sitagliptin + LY2189265

    A single 1.5-milligram (mg) dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2).

    Biological: LY2189265 · Drug: Sitagliptin

  • Experimental
    Sitagliptin + LY2189265, LY2189265

    100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). There was a washout of at least 21 days before crossing over and receiving a single 1.5 mg dose of LY2189265 administered subcutaneously (Treatment 1).

    Biological: LY2189265 · Drug: Sitagliptin

Interventions

  • BiologicalLY2189265

    Administered subcutaneously

    Also known as: Dulaglutide

  • Administered orally

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin

    Area under the sitagliptin pharmacokinetic (PK) concentration versus time curve (AUC \[0-tau\]) during one dosing interval (24 hours) is summarized.

    Time frame: Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2

  2. Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Sitagliptin

    Time frame: Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2

Secondary outcomes

  1. Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Sitagliptin

    Time frame: Predose and up to 24 hours post dose on Day 4, Day 6, and Day 13 of Treatment 2

  2. Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY2189265

    Area under the LY2189265 pharmacokinetic (PK) concentration versus time curve (AUC \[0-tau\]) during one dosing interval (168 hours) is summarized.

    Time frame: Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2

  3. Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of LY2189265

    Time frame: Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2

  4. Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2189265

    Time frame: Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2

07

Results

Posted Oct 7, 2014

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneLY2189265, Sitagliptin + LY2189265Sitagliptin + LY2189265, LY2189265
Started1811
Received at least 1 dose of drug1811
Completed188
Not completed03
Withdrew: Adverse event01
Withdrew: Withdrawal by subject02
Washout of at Least 21 Days
Participant flow — Washout of at Least 21 Days
MilestoneLY2189265, Sitagliptin + LY2189265Sitagliptin + LY2189265, LY2189265
Started188
Completed188
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneLY2189265, Sitagliptin + LY2189265Sitagliptin + LY2189265, LY2189265
Started188
Completed168
Not completed20
Withdrew: Withdrawal by subject10
Withdrew: Adverse event10

Outcome measures

PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin

Area under the sitagliptin pharmacokinetic (PK) concentration versus time curve (AUC \[0-tau\]) during one dosing interval (24 hours) is summarized.

Time frame:
Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2
Reported as:
Geometric mean · nanograms times hour/milliliter(ng*h/mL)
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin
nanograms times hour/milliliter(ng*h/mL)100 mg Sitagliptin (Day 4)100 mg Sitagliptin + 1.5 mg LY2189265 (Day 6)100 mg Sitagliptin + 1.5 mg LY2189265 (Day 13)
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin3210 ± 343240 ± 362970 ± 54
PrimaryPharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Sitagliptin
Time frame:
Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Sitagliptin
nanograms/milliliter (ng/mL)100 mg Sitagliptin (Day 4)100 mg Sitagliptin + 1.5 mg LY2189265 (Day 6)100 mg Sitagliptin + 1.5 mg LY2189265 (Day 13)
Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Sitagliptin417 ± 46374 ± 61318 ± 77
SecondaryPharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Sitagliptin
Time frame:
Predose and up to 24 hours post dose on Day 4, Day 6, and Day 13 of Treatment 2
Reported as:
Median · hours
Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Sitagliptin
hours100 mg Sitagliptin (Day 4)100 mg Sitagliptin + 1.5 mg LY2189265 (Day 6)100 mg Sitagliptin + 1.5 mg LY2189265 (Day 13)
Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Sitagliptin1.00 (0.500 to 4.00)2.00 (0.500 to 16.0)2.00 (0.500 to 12.0)
SecondaryPharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY2189265

Area under the LY2189265 pharmacokinetic (PK) concentration versus time curve (AUC \[0-tau\]) during one dosing interval (168 hours) is summarized.

Time frame:
Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2
Reported as:
Geometric mean · nanograms times hour/milliliter(ng*h/mL)
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY2189265
nanograms times hour/milliliter(ng*h/mL)1.5 mg LY2189265 (Day 1)100 mg Sitagliptin + 1.5 mg LY2189265 (Day 5)100 mg Sitagliptin + 1.5 mg LY2189265 (Day 12)
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY21892656590 ± 408890 ± 2613900 ± 26
SecondaryPharmacokinetics: Maximum Observed Drug Concentration (Cmax) of LY2189265
Time frame:
Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of LY2189265
nanograms/milliliter (ng/mL)1.5 mg LY2189265 (Day 1)100 mg Sitagliptin + 1.5 mg LY2189265 (Day 5)100 mg Sitagliptin + 1.5 mg LY2189265 (Day 12)
Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of LY218926552.9 ± 3768.1 ± 25101 ± 28
SecondaryPharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2189265
Time frame:
Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2
Reported as:
Median · hours
Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2189265
hours1.5 mg LY2189265 (Day 1)100 mg Sitagliptin + 1.5 mg LY2189265 (Day 5)100 mg Sitagliptin + 1.5 mg LY2189265 (Day 12)
Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY218926572.0 (12.0 to 120)72.0 (48.0 to 144)59.8 (12.0 to 120)

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2189265—0/26 (0%)11/26 (42.3%)
Sitagliptin—0/29 (0%)10/29 (34.5%)
Sitagliptin + LY2189265—2/29 (6.9%)16/29 (55.2%)
Most frequent serious events
Most frequent serious events
EventLY2189265SitagliptinSitagliptin + LY2189265
Pneumonia bacterialInfections and infestations0/260/291/29
ConcussionInjury, poisoning and procedural complications0/260/291/29
Renal failure acuteRenal and urinary disorders0/260/291/29
Most frequent other events
Showing 10 of 45
Most frequent other events
EventLY2189265SitagliptinSitagliptin + LY2189265
HeadacheNervous system disorders4/261/295/29
NauseaGastrointestinal disorders1/260/294/29
Decreased appetiteMetabolism and nutrition disorders1/260/294/29
HypoglycaemiaMetabolism and nutrition disorders1/261/294/29
FatigueGeneral disorders3/261/292/29
Abdominal discomfortGastrointestinal disorders2/260/290/29
DyspepsiaGastrointestinal disorders2/260/291/29
Injection site painGeneral disorders2/260/291/29
Abdominal painGastrointestinal disorders0/260/292/29
DiarrhoeaGastrointestinal disorders1/260/292/29

Baseline characteristics

Participants who received at least one dose of study drug (LY2189265 or Sitagliptin).

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean52.7 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female10
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Entire Study Population
Hispanic or Latino5
Not Hispanic or Latino24
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Entire Study Population
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American14
White11
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Entire Study Population
United States29
08

Study locations

3 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Daytona Beach, Florida 32117, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Honolulu, Hawaii 96814, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75247, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2011
First posted
Aug 3, 2011
Start
Aug 2011
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Oct 7, 2014
Last update
Oct 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01408888
Responsible party
Sponsor
First posted
Aug 3, 2011
Start date
Aug 2011
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Oct 7, 2014
Last update
Oct 7, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion